Shelley R Salpeter

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroids
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, California, USA
    Expert Opin Drug Saf 9:407-19. 2010
  2. doi request reprint Systematic review of noncancer presentations with a median survival of 6 months or less
    Shelley R Salpeter
    Stanford University School of Medicine, CA, USA
    Am J Med 125:512.e1-6. 2012
  3. doi request reprint Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review
    Shelley R Salpeter
    Stanford University School of Medicine, Stanford, Calif Electronic address
    Am J Med 127:124-131.e3. 2014
  4. pmc The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    J Palliat Med 16:616-22. 2013
  5. doi request reprint Systematic review of cancer presentations with a median survival of six months or less
    Shelley R Salpeter
    Sutter Care at Home, San Mateo, CA, USA
    J Palliat Med 15:175-85. 2012
  6. pmc Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    J Gen Intern Med 21:1011-9. 2006
  7. ncbi request reprint Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Clin Rev Allergy Immunol 31:219-30. 2006
  8. pmc Should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? YES
    Shelley R Salpeter
    Department of Medicine at Stanford University School of Medicine, Calif, USA
    Can Fam Physician 53:1290-7. 2007
  9. pmc Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Int J Chron Obstruct Pulmon Dis 2:11-8. 2007
  10. doi request reprint Meta-analysis: metformin treatment in persons at risk for diabetes mellitus
    Shelley R Salpeter
    Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    Am J Med 121:149-157.e2. 2008

Detail Information

Publications34

  1. doi request reprint An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroids
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, California, USA
    Expert Opin Drug Saf 9:407-19. 2010
    ..Until recently, it was unclear whether concomitant inhaled corticosteroids (ICSs) could eliminate this risk...
  2. doi request reprint Systematic review of noncancer presentations with a median survival of 6 months or less
    Shelley R Salpeter
    Stanford University School of Medicine, CA, USA
    Am J Med 125:512.e1-6. 2012
    ..We report on clinical indicators of 6-month mortality in advanced noncancer illnesses and the effect of treatment on survival...
  3. doi request reprint Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review
    Shelley R Salpeter
    Stanford University School of Medicine, Stanford, Calif Electronic address
    Am J Med 127:124-131.e3. 2014
    ..We systematically evaluated the impact of various transfusion triggers on clinical outcomes...
  4. pmc The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    J Palliat Med 16:616-22. 2013
    ..Opioid dose escalation may cause hyperalgesia, mediated by the N-methyl-D-aspartate (NMDA) pathway. Methadone is an atypical opioid that inhibits hyperalgesia through NMDA-blockade, especially at low doses...
  5. doi request reprint Systematic review of cancer presentations with a median survival of six months or less
    Shelley R Salpeter
    Sutter Care at Home, San Mateo, CA, USA
    J Palliat Med 15:175-85. 2012
    ..To report cancer presentations with a median survival of 6 months or less and the effect of treatment on survival...
  6. pmc Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    J Gen Intern Med 21:1011-9. 2006
    ..Anticholinergics and beta2-agonists have generally been considered equivalent choices for bronchodilation in chronic obstructive pulmonary disease (COPD)...
  7. ncbi request reprint Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Clin Rev Allergy Immunol 31:219-30. 2006
    ..beta-Agonists increase respiratory deaths in COPD, possibly as a result of poorer disease control...
  8. pmc Should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? YES
    Shelley R Salpeter
    Department of Medicine at Stanford University School of Medicine, Calif, USA
    Can Fam Physician 53:1290-7. 2007
  9. pmc Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Int J Chron Obstruct Pulmon Dis 2:11-8. 2007
    ..These results indicate that anticholinergics should be the bronchodilator of choice in COPD, while beta-agonists may be associated with poorer disease control...
  10. doi request reprint Meta-analysis: metformin treatment in persons at risk for diabetes mellitus
    Shelley R Salpeter
    Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    Am J Med 121:149-157.e2. 2008
    ..We performed a meta-analysis of randomized controlled trials to assess the effect of metformin on metabolic parameters and the incidence of new-onset diabetes in persons at risk for diabetes...
  11. doi request reprint Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events
    Shelley R Salpeter
    Stanford University School of Medicine, Stanford, CA, USA
    Am J Med 123:322-8.e2. 2010
    ..We pooled data on long-acting beta-agonists with variable and concomitant inhaled corticosteroids to evaluate the risk for catastrophic asthma events...
  12. doi request reprint Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women
    Shelley R Salpeter
    Santa Clara Valley Medical Center, 751 S Bascom Ave, San Jose, CA 95128, USA
    Am J Med 122:1016-1022.e1. 2009
    ..This analysis synthesizes evidence from different sources, taking into account varying views on the issue...
  13. doi request reprint The cost-effectiveness of hormone therapy in younger and older postmenopausal women
    Shelley R Salpeter
    Department of Medicine, Santa Clara Valley Medical Center, San Jose, Calif 95128, USA
    Am J Med 122:42-52.e2. 2009
    ..To evaluate the health and economic outcomes of hormone therapy in younger and older postmenopausal women...
  14. ncbi request reprint Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women
    S R Salpeter
    Stanford University School of Medicine, Stanford, CA, USA
    Diabetes Obes Metab 8:538-54. 2006
    ..To quantify the effects of hormone-replacement therapy (HRT) on components of the metabolic syndrome in postmenopausal women...
  15. ncbi request reprint Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs
    Shelley R Salpeter
    Stanford University School of Medicine, Stanford, California, USA
    Am J Med 119:552-9. 2006
    ..We performed a meta-analysis of randomized controlled trials to assess the effect of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) on cardiovascular events in trials of joint disease and Alzheimer's disease...
  16. ncbi request reprint Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis
    S R Salpeter
    Stanford University School of Medicine, CA, USA
    Respir Med 97:1094-101. 2003
    ..Given their demonstrated benefit in conditions such as heart failure, coronary artery disease and hypertension, cardioselective beta-blockers should be considered for patients with COPD...
  17. ncbi request reprint Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Arch Intern Med 163:2594-602. 2003
    ..The true incidence of fatal and nonfatal lactic acidosis associated with metformin use is not known...
  18. ncbi request reprint Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review
    Shelley R Salpeter
    Stanford University School of Medicine, Stanford, California, USA
    Drugs Aging 21:405-14. 2004
    ....
  19. ncbi request reprint Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis
    Shelley R Salpeter
    Santa Clara Valley Medical Center, San Jose, CA, USA
    Chest 125:2309-21. 2004
    ..beta(2)-Agonist use in patients with obstructive airway disease has been associated with an increased risk for myocardial infarction, congestive heart failure, cardiac arrest, and acute cardiac death...
  20. pmc Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis
    Shelley R Salpeter
    Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    J Gen Intern Med 19:791-804. 2004
    ..To assess mortality associated with hormone replacement in younger and older postmenopausal women...
  21. pmc Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis
    Shelley R Salpeter
    Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    J Gen Intern Med 21:363-6. 2006
    ..To assess the effect of hormone therapy (HT) on coronary heart disease (CHD) events in younger and older postmenopausal women...
  22. ncbi request reprint Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths
    Shelley R Salpeter
    Santa Clara Valley Medical Center, San Jose, California 95128, USA
    Ann Intern Med 144:904-12. 2006
    ..Long-acting beta-agonists may increase the risk for fatal and nonfatal asthma exacerbations...
  23. doi request reprint Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence
    Shelley R Salpeter
    Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA
    Drugs 69:2025-33. 2009
    ..It is possible that the reduction in respiratory morbidity could improve functional status and reduce adverse cardiac outcomes over time. Further studies are needed to address this important issue...
  24. ncbi request reprint Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
    Shelley R Salpeter
    Medicine, Stanford University, and Santa Clara Valley Medical Center, 2400 Moorpark Ave, Suite 118, San Jose, CA, USA, 95128
    Cochrane Database Syst Rev 4:CD002967. 2010
    ....
  25. ncbi request reprint Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis
    Shelley R Salpeter
    Stanford University School of Medicine, Palo Alto, California, USA
    Ann Intern Med 137:715-25. 2002
    ..To assess the effect of cardioselective beta-blockers on respiratory function of patients with reactive airway disease...
  26. ncbi request reprint Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma
    Shelley R Salpeter
    Stanford University School of Medicine, Stanford, USA
    Ann Intern Med 140:802-13. 2004
    ..The regular administration of beta2-agonists may be associated with the development of tolerance to their effects...
  27. doi request reprint Two cardiovascular risk factors in one? Homocysteine and its relation to glomerular filtration rate. A meta-analysis of 41 studies with 27,000 participants
    Jan T Kielstein
    Department of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California 94305 5406, USA
    Kidney Blood Press Res 31:259-67. 2008
    ..We performed a meta-analysis of studies that report correlations between glomerular filtration rate (GFR) and homocysteine plasma levels...
  28. doi request reprint Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis
    Albert Y Lin
    Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    Clin Colorectal Cancer 10:63-9. 2011
    ..Emerging data suggest that somatic KRAS mutation in advanced colorectal cancer is a strong predictor of non-response to anti-epidermal growth factor receptor antibody (anti-EGFR) therapy...
  29. doi request reprint Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: A systematic review and meta-analysis
    An Ting T Lu
    Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    Clin Colorectal Cancer 8:207-14. 2009
    ..We performed a systematic review and meta-analysis of gene expression profiles (GEPs) to assess their utility for risk stratification and prediction of poor outcomes in stage II CRC...
  30. ncbi request reprint Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis
    Shelley R Salpeter
    Santa Clara Valley Medical Center, San Jose, USA
    Infect Control Hosp Epidemiol 25:1056-61. 2004
    ..To evaluate cost-effective screening and treatment strategies for healthcare workers (HCWs) at risk for tuberculosis exposure...
  31. ncbi request reprint Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway disease: moving from myth to evidence-based practice
    Thomas M Ormiston
    Stanford University School of Medicine and Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    Heart Fail Monit 4:45-54. 2003
    ..This article will review the evidence concerning the safety of beta-blocker use in patients with CHF and concomitant obstructive lung disease, with specific attention to tracking the transition from myth to evidence- based practice...
  32. ncbi request reprint Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis
    Jan T Kielstein
    Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305 5406, USA
    Nephrol Dial Transplant 21:2446-51. 2006
    ..The purpose of this analysis was to identify the role of symmetric dimethylarginine (SDMA), the structural isomer of the cardiovascular risk marker asymmetric dimethylarginine, as an endogenous marker of renal function...
  33. ncbi request reprint Systematic review: the effects of growth hormone on athletic performance
    Hau Liu
    Santa Clara Valley Medical Center, San Jose, California 95128, USA
    Ann Intern Med 148:747-58. 2008
    ..Human growth hormone is reportedly used to enhance athletic performance, although its safety and efficacy for this purpose are poorly understood...
  34. pmc Rebuttal: should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? Yes
    Shelley R Salpeter
    Can Fam Physician 53:1429-30, 1432-3. 2007